Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Forest Labs Fiscal 4Q Profit Plunges

By Pharmaceutical Processing | April 23, 2013

Forest Laboratories Inc.’s fiscal fourth-quarter earnings plunged 76 percent, as the drug developer’s revenue continued to take a hit from a key patent loss.

The New York company said Tuesday that it earned $45.4 million, or 17 cents per share, in the three months that ended March 31. That compares with earnings of $192.7 million, or 72 cents per share, in last year’s quarter.

Excluding acquisition-related items, earnings totaled 25 cents per share. Revenue fell 22 percent to $821.7 million.

Forest’s sales have dropped since its anxiety and depression drug Lexapro lost patent protection in March 2012. Revenue from other drugs has climbed. Sales of the Alzheimer’s disease treatment Namenda rose nearly 12 percent to $438.8 million, and the company also recorded more revenue from some newer drugs.

Sales of the major depressive disorder treatment Viibryd jumped 79 percent to $44.6 million, and revenue from the high blood pressure treatment Bystolic rose 36 percent to $132 million.

For the full year, Forest Laboratories lost $32.1 million, or 12 cents per share, on $3.13 billion in revenue. It was the company’s first annual loss since fiscal 1997

Chairman and CEO Howard Solomon said in a statement that Forrest Laboratories hit an earnings trough created by the loss of the Lexapro patent and expenses that came from launching several drugs. But he said the drug developer appears to be headed up and he expects earnings to grow, helped by the newer products.

Forest Laboratories expects adjusted earnings of 80 cents to $1 per share on about $3.5 billion in fiscal 2014.

Its shares rose 69 cents to $36.83 in morning trading amid broader market gains.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE